spacer
home > ebr > summer 2002 > good news for european bioinformatics - the database right
PUBLICATIONS
European Biopharmaceutical Review

Good News for European Bioinformatics - The Database Right

Scientific research is reliant upon databases of ever-increasing size and sophistication. It is vital for any business which exploits such databases - whether as an owner or as a licensee - to understand the way in which the law protects them. In Europe, companies creating databases can benefit from a special form of protection called 'database right' (sometimes called 'sui generis right'). This right is distinct from, and additional to, any copyright or other intellectual property right which may subsist in the database and its contents. Its focus is on protecting investment in databases. Database right is not available to companies based in countries outside Europe and which have not agreed to reciprocal protection for databases. The US is an important example of a country where database right is currently not available.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Daniel Pavin, a Solicitor Specialising in Intellectual Property

and Information Technology Law with Taylor Joynson Garrett
Daniel Pavin is a Solicitor specialising in intellectual property and information technology law. Daniel advises a wide range of clients, and has a particular focus on clients in the pharmaceutical, biotechnology and information technology sectors. He has a Diploma in Intellectual Property Law and Practice from Bristol University, UK.
Daniel has a degree from Cambridge University in Computer Science and Physics and worked as a Computer Programmer before qualifying as a Solicitor.

spacer
Daniel Pavin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Companyís novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developerís mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Irelandís premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement